Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells

Inhibition of the HSP90 chaperone results in depletion of many signaling proteins that drive tumorigenesis, such as downstream effectors of KRAS, the most commonly mutated human oncogene. As a consequence, several small-molecule HSP90 inhibitors are being evaluated in clinical trials as anticancer a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rouhi, Arefeh, Miller, Christina, Grasedieck, Sarah, Reinhart, Stefanie, Stolze, Britta, Döhner, Hartmut, Kuchenbauer, Florian, Bullinger, Lars, Fröhling, Stefan, Scholl, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352352/
https://www.ncbi.nlm.nih.gov/pubmed/28032595
http://dx.doi.org/10.18632/oncotarget.13841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352352/
https://www.ncbi.nlm.nih.gov/pubmed/28032595
http://dx.doi.org/10.18632/oncotarget.13841

Ejemplares similares